Filing Details

Accession Number:
0001179110-13-008495
Form Type:
4
Zero Holdings:
No
Publication Time:
2013-05-15 18:51:11
Reporting Period:
2013-05-13
Filing Date:
2013-05-15
Accepted Time:
2013-05-15 18:51:11
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1012140 Onyx Pharmaceuticals Inc ONXX Biological Products, (No Disgnostic Substances) (2836) 943154463
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1397266 K Matthew Fust C/O Onyx Pharmaceuticals, Inc.
249 E. Grand Ave.
South San Francisco CA 94080
Evp & Chief Financial Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2013-05-13 10,269 $34.48 60,473 No 4 M Direct
Common Stock Disposition 2013-05-13 4,269 $97.54 56,204 No 4 S Direct
Common Stock Disposition 2013-05-13 6,000 $98.70 50,204 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Disposition 2013-05-13 10,269 $0.00 10,269 $34.48
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
41,450 2019-01-05 No 4 M Direct
Footnotes
  1. Shares sold pursuant to a 10b5-1 plan.
  2. The shares were sold at prices ranging from $97.2301 to $98.1201. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
  3. The shares were sold at prices ranging from $98.45 to $98.92. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
  4. Fully vested.